Back

Prognostic value of cardiac biomarkers in patients with transthyretin deposition cardiac amyloidosis.

29 June 2021 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: ePoster session Biomarkers HFA Premium Access Heart Failure 2021

About the speaker

Photo
Doctor Miguel Fernandez de Sanmamed Giron

University Hospital Dr Negrin, Las Palmas de Gran Canaria (Spain)

738 More presentations in this session

Presentation thumbnail
Atrial lead insertion during cardiac implantable electronic devices implantation in patients with atrial arrhythmia on hospital admission, when does the struggle for sinus rhythm make sense?
Assistant Professor N. Radovanovic (Belgrade, RS)
Abstract Slides
Presentation thumbnail
Features of the remodeling of atria and pulmonary veins in CHF patients with paroxysmal AF and permanent AF
Assistant Professor V. Kirillova (Ekaterinburg, RU)
Abstract Slides
Presentation thumbnail
Rhythm control versus rate control in patients with atrial fibrillation and heart failure across the left ventricular ejection fraction spectrum
Doctor D. Moysidis (Zurich, CH)
Abstract Slides
Presentation thumbnail
Impact of cardiac contractility modulation on ventricular rhythm and conduction disorders in patients with heart failure with reduced ejection fraction and various forms of atrial fibrillation
Doctor A. Safiullina (Moscow, RU)
Abstract Slides
Presentation thumbnail
Was a difference between late and early new-onset of atrial fibrillation in non st-elevation myocardial infarction?
Doctor H. Santos (Lisboa, PT)
Abstract Slides

Access the full session

Session thumbnail
ePoster session

The Event

Event poster

Heart Failure 2021

29 June - 1 July 2021
You may be interested in
thumbnail
Congress Presentation
The role of a multimarker panel in the diagnosis and prognosis of patients with acute heart failure
thumbnail
Congress Session
From genetic signatures to clinical implications
thumbnail
Congress Presentation
Growth differentiation factor 15 and absorption loss as new biomarkers of heart failure decompensation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources